it must only be used within a registered clinical trial or approved early-access programme
For patients with high coinsurance ($4,000-$6,000 annually), retatrutide costs more than surgery after 3-4 years
In retatrutides TRIUMPH-1 trial, the highest-dose group reported nausea in 42.4% of participants, diarrhea in 32.0%, constipation in 26.1%, and vomiting in 25.3% a higher overall GI burden, which tracks with retatrutides larger effect size and third receptor target
Fermented Foods Foods that have gone through fermentation, like yogurt, kefir, and kimchi, are packed with probiotics
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
